Šárka Němečková

Dr. Šárka Němečková

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
MŠMarkéta Šťastná-Marková
Markéta Šťastná-Marková
EHEva Hamšíková
Eva Hamšíková
PHPetr Hainz
Petr Hainz
PHPetr Hubáček
Petr Hubáček
MKMarie Kroutilová
Marie Kroutilová
ŠNŠárka Němečková
Šárka Němečková
BK polyomavirus (BKPyV) persists lifelong in renal and urothelial cells with asymptomatic urinary shedding in healthy individuals. In some immunocompromised persons after transplantation of hematopoietic stem cells (HSCT), the BKPyV high-rate replication is associated with haemorrhagic cystitis (HC). We tested whether the status of BKPyV immunity prior to HSCT could provide evidence for the BKPyV tendency to reactivate. We have shown that measurement of pretransplant anti-BKPyV 1 and 4 IgG levels can be used to evaluate the HC risk. Patients with anti-BKPyV IgG in the range of the 1st–2nd quartile of positive values and with positive clinical risk markers have a significantly increased HC risk, in comparison to the reference group of patients with “non-reactive” anti-BKPyV IgG levels and with low clinical risk (LCR) (p = 0.0009). The predictive value of pretransplant BKPyV-specific IgG was confirmed by determination of genotypes of the shed virus. A positive predictive value was also found for pretransplant T-cell immunity to the BKPyV antigen VP1 because the magnitude of IFN-γ T-cell response inversely correlated with posttransplant DNAuria and with HC. Our novel data suggest that specific T-cells control BKPyV latency before HSCT, and in this way may influence BKPyV reactivation after HSCT. Our study has shown that prediction using a combination of clinical and immunological pretransplant risk factors can help early identification of HSCT recipients at high risk of BKPyV disease.

17 May 2023 in Leukemia Research
Verified
Journal Article
Closed access
JMJana Macková
Jana Macková
PHPetr Hainz
Petr Hainz
JKJitka Kryštofová
Jitka Kryštofová
KRKateřina Roubalová
Kateřina Roubalová
MŠMarkéta Šťastná-Marková
Markéta Šťastná-Marková
ŠNŠárka Němečková
Šárka Němečková

20 April 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
ŠNŠárka Němečková
Šárka Němečková
KZKAMILA ALEXOVA ZURKOVA
KAMILA ALEXOVA ZURKOVA
PHPetr Hainz
Petr Hainz
JKJitka Krystofova
Jitka Krystofova
JMJana Macková
Jana Macková
JVJan Vydra
Jan Vydra
Nucleophosmin (NPM1, B23) is a multifunctional phosphoprotein expressed in all tissues. The protein is mainly localized in nucleoli. In hematological malignancies, NPM1 belongs to commonly altered genes. Its mutation, always heterozygous, leads to the re-localization of the NPM1 protein from the nucleolus to the cytoplasm (NPM1c+). NPM1c+ is found in 30% of acute myeloid leukemia (AML). Our study showed that an AML patient, whose leukemia cells carried the NPM1c+ mutation and who was the recipient of allogeneic HSCT from a haploidentical donor, raised a robust allorestricted CD8+ T cell response directed against the NPM1wt protein. Favourably, the response against NPM1wt was not accompanied by side effects such as GvHD. Moreover, the induction of a high NPM1wt-specific response coincided with the decrease in NPM1c+ transcripts detected, implying a beneficial graft versus leukemia effect. On the basis of these results, we suppose that TCRs from allorestricted NPM1wt-specific T cells are worth studying in other recipients of grafts from haploidentical donors as a possible tool for TCR gene therapy.

12 June 2021 in medRxiv
Verified
Preprint
Open access
PDF file
MŠMarkéta Šťastná-Marková
Markéta Šťastná-Marková
EHEva Hamšíková
Eva Hamšíková
PHPetr Hainz
Petr Hainz
PHPetr Hubáček
Petr Hubáček
MKMarie Kroutilová
Marie Kroutilová
ŠNŠárka Němečková
Šárka Němečková
BK polyomavirus (BKV) persists lifelong in the urinary tract with asymptomatic urinary shedding in healthy individuals. In immunocompromised persons after transplantation of hematopoietic stem cells (HSCT) the BKV high-rate replication is associated with haemorrhagic cystitis (HC) with a reported incidence of 17 %. Numerous studies of reconstitution of the immune system after HSCT have established the principal role of T cell effectors in the control of viral replication and reactivation. The value of pretransplant BKV-specific antibodies in transplanted patients for the protection from viral disease was long considered insignificant. We hypothesized that the status of BKV immunity prior to HSCT could provide evidence for the BKV tendency to reactivate and that examining the level of subtype-specific antibodies and T-cell response in individual patients could help to predict the risk of BKV reactivation and HC. Evaluation of the risk of HC in relation to pretransplant anti-BKV1,2,4 IgG levels together with clinical factors known before transplantation revealed that patients with „medium” anti-BKV IgG and significant clinical risk (SR) have a very significantly increased HC risk in comparison with the reference group of “low” anti-BKV IgG level and low clinical risk (LR) (P=0.0009). Predictive value of pretransplant BKV specific IgG was confirmed on the level of virus genotypes. Analysis of pretransplant T cell immunity to BKV antigens VP1 and LTag has shown that magnitude of IFN-gamma T cell response inversely corelated with posttransplant DNAuria. We hypothesize that the control of BKV latency by BKV specific T cells before HSCT would be one of the factors that influence BKV reactivation after HSCT. Our study has shown that prediction using a combination of clinical and immunological pretransplant risk factors can help early identification of patients who are at risk of developing BKV disease after HSCT.


22 September 2002
Verified
Journal Article
Closed access
ŠNŠárka Němečková
Šárka Němečková
LKL Kutinová
L Kutinová
PHP Hainz
P Hainz
JSJ Subrtová
J Subrtová
POP Otáhal
P Otáhal
PGP Gabriel
P Gabriel